Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Cost of Revenue: 2016-2024

Historic Cost of Revenue for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $254.1 million.

  • Collegium Pharmaceutical's Cost of Revenue rose 28.29% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.9 million, marking a year-over-year increase of 43.60%. This contributed to the annual value of $254.1 million for FY2024, which is 5.61% up from last year.
  • Collegium Pharmaceutical's Cost of Revenue amounted to $254.1 million in FY2024, which was up 5.61% from $240.6 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Cost of Revenue registered a high of $254.4 million during FY2022, and its lowest value of $126.3 million during FY2021.
  • For the 3-year period, Collegium Pharmaceutical's Cost of Revenue averaged around $249.7 million, with its median value being $254.1 million (2024).
  • As far as peak fluctuations go, Collegium Pharmaceutical's Cost of Revenue tumbled by 32.78% in 2020, and later spiked by 101.54% in 2022.
  • Collegium Pharmaceutical's Cost of Revenue (Yearly) stood at $130.2 million in 2020, then declined by 3.02% to $126.3 million in 2021, then spiked by 101.54% to $254.4 million in 2022, then dropped by 5.44% to $240.6 million in 2023, then increased by 5.61% to $254.1 million in 2024.